SciELO - Scientific Electronic Library Online

vol.25 suppl.1Brugada syndrome: a 9 year retrospective analysisDoenças raras do metabolismo em doentes com não compactação do ventrículo esquerdo índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados

  • Não possue artigos similaresSimilares em SciELO


Nascer e Crescer

versão impressa ISSN 0872-0754

Nascer e Crescer vol.25  supl.1 Porto dez. 2016





Fabry disease in portugal – insights from the male patients



Ana Rita Soares1; Francisco Laranjeira2; Carla Caseiro2; Isaura Ribeiro2; Elisabete Silva2; Eugénia Pinto2; Célia Ferreira2; Sónia Rocha2; Ana Fortuna1; Dulce Quelhas2; Lúcia Lacerda2

1Medical Genetics Unit, Centro Genética Médica Doutor Jacinto Magalhães, Centro Hospitalar do Porto, Porto
2Biochemical Genetics Unit, Centro Genética Médica Doutor Jacinto Magalhães, Centro Hospitalar do Porto, Porto




Introduction: Fabry disease (FD, MIM #301500) is a rare X-linked metabolic disorder with progressive multisystemic clinical course, caused by partial or complete deficiency of a-galactosidase A (a-Gal A), a lysosomal enzyme encoded by GLA gene mapped at Xq22.1. The enzymatic defect leads to progressive lysosomal accumulation of the glycolipid globotriaosylceramide in most organs. Clinically, Fabry patients may be divided into two groups: classic and atypical, depending on the age, symptoms and organs involved at diagnosis. The diagnosis in males is based on a deficient a-Gal A enzymatic activity in plasma, leucocytes or dried blood spot, and/or identification of a pathogenic mutation. Reports tend to establish a correlation between the severity of the disease and the degree of a-Gal A deficiency. This work aims to characterize Portuguese FD male patients according to clinical, geographical, biochemical and genetic profile.

Methods: As national reference centre, our laboratory tests most Portuguese FD patients. We performed a retrospective analysis concerning the laboratory determinations, age at diagnosis, district of origin and the main clinical manifestation (according to medical speciality that requested the study).

Results/Discussion: Our cohort includes 80 male patients belonging to 50 different families, being Braga the district with a higher frequency.

Our results revealed a mean age of index cases at diagnosis of 46 years-old, the sixth decade of life the most representative age interval and p.F113L the most prevalent mutation. These facts seem to be correlated, as this mutation is associated with FD late-onset cardiac variant and most patients were studied upon Cardiology request. According to some authors, patients carrying p.F113L mutation are expected to have a high residual enzyme activity; nevertheless our results evidence a severe enzyme deficit (7.3% of the minimum of the control range).

Hereto, we describe three novel genetic variants – c.386T>G (p.L129R), c.607G>T (p.E203*), c.683A>G (p.N228S), besides other puzzling cases.

Conclusion: Due to the prevalence of p.F113L mutation in this FD patients cohort, the authors observed a bias, namely in the age of diagnosis and the clinical variant, when compared with other reports. Furthermore, this study provides an extremely useful tool to establish orientations for an earlier diagnosis, more efficient treatment management and appropriate genetic counselling of patients and their families.

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons